Australia's Cyclopharm gains on FDA approval for lung disease diagnostic agent

Cyclopharm

15/11/2023 03:30

** Shares of Australia's Cyclopharm  CYC.AX  rise as much as
5.8% to A$2.2, marking their biggest intraday gain since Nov 2
    ** Co stock at its highest level since Nov 3
    ** The medical equipment and technology provider says it
received United States Food and Drug Administration (FDA)
approval to start commercial sales of Technegas in the U.S.
market
    ** Technegas is a radioactive diagnostic agent used for
asthma and chronic obstructive pulmonary disease, a lung disease
    ** Stock up 77.8% YTD, as of last close

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))